Work

Efficacy and Safety of Telitacicept in IgA Nephropathy and IgA Vasculitis-Associated Nephritis in Children: A Retrospective Single-Centre Study

Year: 2025

Type: article

Abstract: Background: Childhood IgA nephropathy (IgAN) and IgA Vasculitis-associated nephritis (IgAVN) are same in pathogenesis and still a challenge to pediatricians. Purpose: To evaluate the efficacy and safety of Telitacicept in pediatric patients with IgAN or IgAVN. Patients and Methods: This was a retrospective single-centre study of pediatric IgAN or IgAVN with urine protein-to-creatinine ratio (UPCR) over 500 μg/mg who were treated with subcutaneous administration of Telitacicept and followed for at least 6 months. The effects on induction of remission and side effects were evaluated. Results: 13 pediatric patients including 7 with IgAN and 6 with IgAVN were enrolled in the study. After 6-month treatment, 6 of 13 (46.15%) patients achieved remission, 4 (30.77%) patient achieved complete remission. The median percent reduction in UPCR was 90.74% (84.38%, 94.76%). The median percent reduction in urine red blood cells count was 96.21% (75.33%, 98.99%). Compared with baseline, serum albumin increased significantly [ P < 0.001, 95% CI (− 10.30, − 4.04)], and estimated glomerular filtration rate (eGFR) remained stable and within the normal range. Significant reductions were observed in levels of IgA [ P < 0.001; 95% CI (1.15, 2.49)], IgM [ P = 0.002; 95% CI (0.53, 1.08)], as well as CD19+ lymphocytes [ P = 0.012; 95% CI (6.63, 34.67)]. The average follow-up was 6.5 ± 0.8 months, 5 patients achieved glucocorticoid discontinuation. No severe adverse events were observed. Conclusion: Telitacicept was safe in pediatric IgAN/IgAVN patients and could significantly induce renal remission through reducing proteinuria and hematuria. Keywords: telitacicept, IgA nephropathy, IgA vasculitis-associated nephritis, pediatric, efficacy, safety

Source: Drug Design Development and Therapy

DOI: 10.2147/dddt.s565279